RYOM, L.; DILLING LUNDGREN, J.; REISS, P.; KIRK, O.; LAW, M.; ROSS, M.; MORLAT, Philippe; ANDREAS FUX, C.; FONTAS, E.; DE WIT, S.; D'ARMINIO MONFORTE, A.; EL-SADR, W.; PHILLIPS, A.; INGRID HATLEBERG, C.; SABIN, C.; MOCROFT, A.

doi:10.1093/infdis/jiz369

Métadonnées

Afficher la notice complète

Licence d’utilisation du document

Langue

Article de revue

Ce document a été publié dans

The Journal of infectious diseases. 2019-10-08, vol. 220, n° 10, p. 1629-1634

Résumé en anglais

BACKGROUND: It is unclear whether use of contemporary protease inhibitors pose a similar risk of chronic kidney disease (CKD) as use of older protease inhibitors. METHODS: Participants in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study were followed up until the earliest occurrence of CKD, the last visit plus 6 months, or 1 February 2016. Adjusted Poisson regression was used to assess associations between CKD and the use of ritonavir-boosted atazanavir (ATV/r) or ritonavir-boosted darunavir (DRV/r). RESULTS: The incidence of CKD (10.0/1000 person-years of follow-up; 95% confidence interval, 9.5-10.4/1000 person-years of follow-up) increased gradually with increasing exposure to ATV/r, but the relation was less clear for DRV/r. After adjustment, only exposure to ATV/r (adjusted incidence rate ratio, 1.4; 95% confidence interval, 1.2-1.6), but not exposure to DRV/r (1.0; .8-1.3), remained significantly associated with CKD. CONCLUSION: While DRV/r use was not significantly associated with CKD an increasing incidence with longer ATV/r use was confirmed.< Réduire

Mots clés en anglais

MORPH3Eus

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés en anglais

URI

DOI

Unités de recherche